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Abstract
Background: The optimal duration of dual antiplatelet therapy (DAPT) following drug-
eluting stent (DES) implantation remains a subject of an ongoing debate.
Methods: MEDLINE, EMBASE, Scopus and CENTRAL databases were searched for eligi-
ble randomized controlled trials (RCTs) that compared short-term (£ 6 months) DAPT with 
long-term (≥ 12 months) DAPT following DES implantation. The primary endpoint was a 
composite of all-cause mortality, myocardial infarction (MI), target vessel revascularization 
(TVR), stroke, or major bleeding. The secondary outcome were the individual components of 
the primary outcome, cardiovascular death, stent thrombosis and any bleeding episode.
Results: A total of 15,378 patients from 7 RCTs were studied. There were no statistically sig-
nificant differences between the short-term and long-term DAPT groups with respect to the oc-
currence of the primary outcome (risk ratio [RR] 1.017; 0.872–1.186; I2 = 0%), all cause death 
(RR 0.896; 0.708–1.134), cardiovascular death (RR 0.924; 0.668–1.279), MI (RR 1.139; 
0.887–1.461), TVR (RR 1.174; 0.916–1.505), stent thrombosis (RR 1.264; 0.786–2.032), 
and stroke (RR 0.876; 0.685–1.611). However, there was a statistically significant lower risk 
of major bleeding in the short-term DAPT group (RR 0.57; 0.36–0.90; p = 0.02). There were 
no statistically significant differences in the sub-group analysis of patients with diabetes and 
patients presenting with acute coronary syndrome, RR 1.029; 0.745–1.421 and RR 1.062; 
0.785–1.438, respectively.
Conclusions: There was no difference in efficacy outcomes between short-term and long-term 
DAPT following DES, even among high-risk patients. However, longer duration of DAPT was 
found to be associated with increased risk of major bleeding. (Cardiol J 2016; 23, 3: 307–316)
Keywords: dual antiplatelet therapy, drug-eluting stent, bleeding,  
stent thrombosis
Introduction
Drug-eluting stents (DES) reduce the inci-
dence of target lesion restenosis when compared 
with bare metal stents, yet they are prone to higher 
rates of stent thrombosis [1]. Dual antiplatelet 
therapy (DAPT), defined as the use of both aspirin 
and a P2Y12 receptor inhibitor, such as clopidogrel, 
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prasugrel or ticagrelor, reduces the risk of stent 
thrombosis [2]. However, the optimal duration of 
DAPT following DES implantation at percutane-
ous coronary intervention remains unknown. The 
American Heart Association/American College of 
Cardiology recommend DAPT to be extended to at 
least 12 months after DES implantation if patients 
are not at high risk of bleeding [3]. Conversely, 
the European Society of Cardiology recommends 
from 6 to 12 months of DAPT for patients follow-
ing elective percutaneous coronary intervention 
(PCI) and DES implantation, or 12 months in 
acute coronary syndromes [4]. These guidelines 
are largely based on observational studies which 
showed that early discontinuation of P2Y12 recep-
tor inhibitor therapy increased the risk of stent 
thrombosis [5–7]. Several randomized controlled 
trials (RCTs) comparing various durations of DAPT 
did not find any statistically significant differences 
in stent thrombosis rates [8–16]. However, these 
RCTs were not adequately powered to detect 
a statistically significant difference because of event 
rates being lower than expected and failure to 
recruit enough patients [11, 12, 16]. To address 
this limitation, a few meta-analyses have been 
conducted on the subject [17–22]. However, only 
the meta-analyses of RCTs by Pandit et al. [19], 
Liu et al. [18] and El-Hayek et al. [20] compared ≤ 
6-month DAPT with ≥ 12-month DAPT. Finding 
no difference in efficacy outcomes between short- 
and long-term DAPT in these meta-analyses may 
have also been due to the low overall event rates. 
In addition, no sub-group analyses were performed 
in earlier meta-analyses. Hence, we conducted an 
updated meta-analysis of RCTs to determine the 
efficacy and safety of short-term (£ 6 months) 
DAPT as compared with long-term (≥ 12 months) 
DAPT following DES implantation.
Methods
We conducted a systematic review and meta-
analysis, using methods that are in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement 
recommended by the Cochrane collaboration [23].
Study research
MEDLINE, EMBASE, Scopus and CENTRAL 
databases were systematically searched from in-
ception to January 2015 for all published RCTs in 
humans that compared outcome in patients receiv-
ing short-term (£ 6 months) DAPT with long-term 
(≥ 12 months) DAPT following DES implantation. 
Medical Subject Headings (MeSH) key terms 
‘duration’, ‘dual antiplatelet therapy’, ‘DAPT’, 
‘drug-eluting stent’ and ‘DES’ were used for the 
search. We subsequently searched and evaluated 
all reference lists of eligible articles obtained from 
the electronic search, and online resources such 
as Cardiosource and ClinicalTrials.gov to ensure 
identification of all published and unpublished 
studies on the subject.
Study selection, data extraction  
and endpoints
Two investigators (O.S. and X.P.) independent-
ly identified and scrutinized studies for potential 
inclusion based on title or title and abstract. Full ar-
ticles were then retrieved for further assessment, 
and disagreements were resolved by consensus 
and discussion with a third investigator (B.P.-L.).
The primary endpoint of this analysis was 
a composite of all-cause moralty, myocardial infarc-
tion (MI), target vessel revascularization (TVR), 
stroke, or major bleeding. The secondary outcome 
were the individual components of the primary 
outcome, cardiovascular death, stent thrombosis 
and any bleeding episode. Major bleeding was 
also defined according to the Randomized Evalua-
tion of PCI Linking Angiomax to reduced Clinical 
Events (REPLACE-2) as intracranial, intraocular, 
or retroperitoneal bleed, overt blood loss with 
a > 3 g/dL decrease in hemoglobin, any hemoglobin 
decrease > 4 g/dL, or transfusion of ≥ 2 units of 
blood products; or according to the severe or life-
threatening Global Utilization of Streptokinase 
and Tissue plasminogen activator for Occluded 
coronary arteries (GUSTO) criteria as intracranial 
bleeding or bleeding which resulted in substantial 
hemodynamic compromise requiring intervention 
[24–27].
Selection criteria
We applied the following screening criteria to 
determine qualitative eligibility: original article; 
patients at least 18 years of age; duration of follow-
up of at least 1 year; reported primary endpoint; and 
at least 100 patients included. Exclusion criteria 
applied included: on-going RCTs, RCTs comparing 
longer durations of DAPT, non-RCTs, editorial 
comments, reviews, and conference abstracts.
Quality assessment
The methodological quality of each trial was 
evaluated for risk of bias using standard criteria 
in the following areas: method of randomization; 
allocation concealment; patient, investigator, and 
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outcome assessor blinding; selective outcome re-
porting; incomplete outcome ascertainment; and 
other potential sources of bias as recommended by 
the Cochrane collaboration [28].
Statistical analysis
Data from each trial were entered on an in-
tention-to-treat basis. Baseline characteristics 
were summarized and the differences between the 
two groups were compared using the Student’s 
t tests for continuous variables and the c2 test 
categorical variables. The included studies were 
compared with risk ratios (RRs) as the measure of 
effect. Heterogeneity was assessed using Cohran’s 
Q statistic and I2 statistic ([Q – df]/Q × 100) and was 
considered present at p < 0.10 and I2 > 50% [29]. 
Pooling was performed according to the fixed ef-
fect model with summary effect estimates (95% 
confidence intervals). To assess for publication 
bias risk, funnel plots were evaluated.
Sensitivity analysis
Sensitivity analyses examining the robust-
ness of the results were explored by comparing 
fixed-effect results with both random effects and 
Yusuf-Peto models. In addition, each study was 
sequentially removed to see if it impacts the pooled 
effect estimate. Sub-group analyses were per-
formed according to trial duration, age ≥ 65 years, 
and patients with acute coronary syndrome (ACS), 
diabetes, reduced left ventricular ejection fraction 
(LVEF), complex lesions, and multi-vessel disease.
Two-sided p values were calculated, with 
a p value less than 0.05 considered significant for 
all tests. Statistical analyses were performed with 
Comprehensive Meta-Analysis version 3 software.
Results
Database search and other sources totally 
provided 4112 records. Of these records, 3,792 
were excluded for various reasons (Fig. 1). Three 
hundred and twenty abstracts were assessed for 
eligibility from which 83 full articles were re-
trieved. However, only 7 RCTs fulfilled the inclu-
sion and exclusion criteria mentioned above. The 
7 RCTs recruited 15,378 patients across 229 sites 
worldwide (Table 1) [10–16].
Figure 1. Study flow diagram; DAPT — dual antiplatelet therapy; RCTs — randomized controlled trials.
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In order to receive short-term DAPT and 
long-term DAPT, 7672 and 7706 patients were 
randomized, respectively. The two groups studied 
were similar with respect to baseline clinical and 
angiographic characteristics (Table 2). Women 
were under-represented when compared with 
men. All the trials except PRODIGY exclusively 
utilized DES for PCI. In order to maintain con-
sistency in our analysis, we included data from 
the DES subgroup in the PRODIGY trial that was 
subsequently published [14]. Follow-up duration 
was 12 months in 4 trials [10, 13, 15, 16], and 
15 months, 24 months and 36 months in the remain-
ing 3 trials [11, 12, 14]. The composite primary 
end-point was similar in all 7 studies, except for 
the non-inclusion of stroke in 2 studies [10, 15] and 
bleeding in 1 study [14].
Endpoints
The endpoints are shown in Figures 2 and 3.
Primary endpoint. The primary outcome 
occurred in 309 (4.0%) patients who received 
short-term DAPT and in 305 (4.0%) patients who 
received long-term DAPT. There were no statis-
Table 2. Baseline patient clinical and angiographic characteristics.
Variables £ 6-month DAPT (n = 7672) ≥ 6-month DAPT (n = 7706) P
Age [years] 64.1 ± 10.2 64.3 ± 10.4 0.23
Male gender 5595 (72.9%) 5591 (72.6%) 0.98
Hypertension 5942 (77.5%) 6026 (78.2%) 0.94
Diabetes mellitus 2359 (30.7%) 2366 (30.7%) 1.00
Dyslipidemia 5313 (69.3%) 5363 (69.6%) 0.97
Current smoker 1834 (23.9%) 1815 (23.6%) 0.96
Previous MI 1613 (21.0%) 1564 (20.3%) 0.89
Previous PCIa 783 (15.9%) 712 (14.3%) 0.77
Previous CABG 570 (7.4%) 566 (7.3%) 0.97
Congestive heart failureb 895 (14.3%) 904 (14.5%) 0.97
Clinical presentation:
Stable angina/silent ischemia 4177 (54.4%) 4200 (54.5%) 0.99
Unstable angina/NSTEMI 2880 (37.5%) 2891 (37.5%) 1.00
STEMI 416 (5.4%) 434 (5.6%) 0.94
LVEFc 59.0 ± 14.8 58.9 ± 14.2 0.67
Discharge medicationsd:
ACE-inhibitor 555 (31.2%) 592 (33.3%) 0.88
ARB 567 (31.8%) 532 (29.9%) 0.89
Beta-blocker 1139 (64.0%) 1175 (66.0%) 0.92
Statin 1527 (85.7%) 1496 (84.1%) 0.94
Angiographic findings:
Single vessel disease 3948 (51.5%) 3991 (51.8%) 0.97
Multi-vessel disease 3724 (48.5%) 3715 (48.2%) 0.97
LAD lesion 4434 (57.8%) 4446 (57.7%) 0.99
Left circumflex artery lesione 2115 (30.4%) 2069 (29.6%) 0.90
RCA lesione 2515 (36.2%) 2557 (36.6%) 0.96
Left main lesione 48 (0.69%) 42 (0.60%) 0.93
CABGe 94 (1.4%) 83 (1.2%) 0.88
Complex lesions (ACC/AHA B2, C) 5289 (61.1%) 5187 (59.5%) 0.85
aNo data available from ISAR-SAFE and PRODIGY; bNo data available from PRODIGY and SECURITY; cNo data available from ISAR-SAFE, 
ITALIC and OPTIMIZE; dData available from EXCELLENT and RESET; eNo data available from EXCELLENT; DAPT — dual antiplatelet therapy; 
MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting; STEMI — ST elevation MI; 
NSTEMI — non-ST elevation MI; LVEF — left ventricular ejection fraction; ACE — angiotensin converting enzyme; ARB — angiotensin recep-
tor blocker; LAD — left anterior descending coronary artery; RCA — right coronary artery; ACC — American College of Cardiology; AHA — 
American Heart Association
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Figure 2. Forest plot reporting the risk ratios with 95% confidence intervals (CI) (designated lower limit and upper limit) 
of the primary outcome (A) and major bleeding (B) in patients from 7 randomized controlled trials treated with short- 
-term (£ 6 months) dual antiplatelet therapy (DAPT) compared with patients treated with long-term (≥ 12 months) DAPT.
tically significant differences between the short-
term and long-term DAPT groups with respect to 
the occurrence of the primary outcome (pooled 
risk ratio [pRR] 1.02; 0.87–1.19; I2 = 0%) (Fig. 2).
Secondary endpoints. There was no sta-
tistically significant difference in risk of all-cause 
mortality (pRR 0.90; 0.71–1.13; I2 = 0%), cardio-
vascular death (pRR 0.92; 0.67–1.28; I2 = 0%), MI 
(pRR 1.14; 0.89–1.46; I2 = 0%), stent thrombosis 
(pRR 1.264; 0.79–2.03; I2 = 0%), TVR (pRR 1.17; 
0.91–1.51; I2 = 0%), and cerebrovascular acci-
dents (pRR 0.88; 0.69–1.61; I2 = 0%), between 
short and long duration of DAPT. However, major 
bleeding occurred in 28 (0.4%) patients in the 
short-term DAPT group and in 51 (0.7%) patients 
who received long-term DAPT. As shown in Fig-
ures 2 and 3, there was a significantly lower risk 
of major bleeding with short-term DAPT when 
compared with the long-term DAPT group (pRR 
0.57; 0.36–0.90; I2 = 0%; p = 0.02).
Sensitivity and sub-group analyses
Similar results were obtained when analysis 
was performed using the fixed-effects, random ef-
fects and Yusuf-Peto models. Sequential removal 
of each study from the analysis did not impact 
the pooled effect estimate. As shown in Figure 3, 
there was no statistically significant difference 
in risk of the primary endpoint among patients 
presenting with ACS (pRR 1.06; 0.79–1.44; 
I2 = 0%), patients with diabetes (pRR 1.03; 0.75–1.42; 
I2 = 0%), reduced LVEF (pRR 0.81; 0.44–1.49; 
I2 = 0%), complex lesions (pRR 1.00; 0.75–1.33; 
I2 = 0%), multi-vessel disease (pRR 1.24; 0.88– 
–1.73; I2 = 0%), and patients at least 65 years of age 
(pRR 0.83; 0.75–1.33; I2 = 0%) who received short-
-term DAPT as compared with long-term DAPT.
There was no statistically significant difference 
in risk of the primary endpoint between patients 
treated with 3–6 months of DAPT vs. 12-month 
DAPT (pRR 1.04; 0.87–1.25; I2 = 0%), 6 months 
vs. 12 months of DAPT (pRR 1.09; 0.81–1.46; 
I2 = 0%), 3 months vs. 12 months of DAPT 
(pRR 1.01; 0.79–1.30; I2 = 0%), or 6 months vs. 
24 months of DAPT (pRR 0.95; 0.69–1.31; I2 = 0%).
Discussion
Findings
In our meta-analysis of 15,378 patients who 
received DES following PCI, we did not find any 
difference in risk of the primary outcome, all- 
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-cause mortality, cardiovascular death, MI, TVR, 
stent thrombosis, and cerebrovascular accidents 
between the short-term and long-term DAPT 
groups. However, patients treated with short-term 
DAPT were at a significantly lower risk of major 
bleeding. We did not find any difference in the risk 
of the primary endpoint based on DAPT duration 
and on sub-group analyses, according to age and the 
presence of diabetes, ACS, reduced LVEF, complex 
lesions, or multi-vessel disease.
Comparison with other studies
The findings of this study are similar to the 
3 previously published meta-analyses comparing 
£ 6-month DAPT with ≥ 12-month DAPT [18–20]. 
In addition to the 4 studies included in the El-Hayek 
et al. [20] and Pandit et al. [19] meta-analyses, our 
study included 3 recently published studies: ISAR-
-SAFE, ITALIC and SECURITY [11, 12, 16]. The 
findings from our study are more robust due to the 
sample size, nearly twice as large as those in the 
earlier meta-analysis and due to the performance 
of analyses in high-risk patient sub-groups. Since 
our study is investigating the efficacy and safety 
of even shorter duration of DAPT when compared 
to the standard recommended therapy of at least 
12 months, RCTs with short-term DAPT duration 
more than 6 months were excluded.
Concerns regarding the safety of short-term 
DAPT were raised in the meta-analysis of 8157 
patients by Hayek et al. [20] because of the finding 
of an almost 2-fold (1.75), though non-significant 
risk of stent thrombosis among patients who 
discontinued P2Y12 therapy after 6 months. In 
comparison, the risk of stent thrombosis in our 
study, with almost twice as many patients was 
1.26. Nevertheless, the recently published DAPT 
study with 9961 patients comparing 12-month 
DAPT with 30-month DAPT found a statistically 
significant decrease in the rate of stent thrombosis 
[30], suggesting that the trend of increased risk of 
stent thrombosis found in our study and the earlier 
meta-analyses may become significant if patients 
are followed longer. Even though the DAPT study 
also demonstrated a significant decrease in MI and 
major cardiovascular and cerebrovascular events 
Figure 3. Pooled analysis of studies comparing short-term (£ 6 months) dual antiplatelet therapy (DAPT) with long- 
-term (≥ 12 months); A. Forest plot reporting summary risk ratios with 95% confidence intervals (CI) (designated 
lower limit and upper limit) for the comparison of ≤ 6 months DAPT vs. ≥ 12 months DAPT with respect to the primary 
outcome, all cause death, cardiovascular death, myocardial infarction, definite or probable stent thrombosis, target 
vessel revascularization (TVR), stroke and major bleeding; B. Forest plot reporting summary risk ratios with 95% CI 
of the comparison in various sub-groups; m — months; LVEF — left ventricular ejection fraction.
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(MACCE) with 30 months of DAPT, there was 
a paradoxical increased risk of all-cause mortal-
ity with prolonged DAPT when the analysis was 
conducted at 33 months (hazard ratio [HR] 1.36; 
p = 0.04). Furthermore, the increase in stent 
thrombosis, MI and MACCE with 12-month DAPT 
did not translate to an increased risk of death, as 
there was no difference in death from cardiac or 
vascular causes (HR 1.00; 0.66–1.52 and 0.98; 
0.28–3.39, respectively). Hence prolonging DAPT 
duration to 30 months had no effect on cardiovascu-
lar mortality, but led to an almost 2-fold increase in 
non-cardiovascular mortality (HR 1.86; p = 0.01).
Clinical implications
Our study confirms the finding that £ 6 months 
of DAPT is equally effective as ≥ 12 months of 
DAPT reported by previously published RCTs 
with much smaller sample sizes and potential for 
type II error. In addition, we found that long-term 
DAPT is associated with increased risk of major 
bleeding events. Hence, long-term DAPT has the 
potential of leading to increased morbidity, in ad-
dition to higher cost of treatment and pill burden 
when compared with short-term DAPT.
Strengths and limitations of the study
This is the largest meta-analysis to date on 
RCTs comparing outcome in patients receiving 
£ 6-month DAPT with ≥ 12-month DAPT fol-
lowing DES implantation. All the studies included 
were of high quality and visual inspection of the 
funnel plot did not reveal any evidence of publica-
tion bias. In addition, our meta-analysis is the first 
to demonstrate no difference in outcome between 
short-term and long-term DAPT even among the 
high-risk patient sub-groups, including patients 
presenting with ACS and patients with diabetes, 
severely depressed LVEF, complex lesions, and 
multi-vessel disease.
As expected in any meta-analysis, our study 
utilized data that were reported in each of the in-
cluded RCTs. With the exception of the ISAR-SAFE 
trial, all the included RCTs were not double blind 
but open-label by design, which introduces the pos-
sibility of ascertainment bias in the results. There 
is also a possibility that selection bias may have 
been present, since none of the studies reported 
whether allocation concealment was performed. 
However, there were no differences between the 
two groups in the baseline characteristics of the 
included subjects. Despite pooling data from 15,378 
patients, the total number of stent thrombosis 
events remained low (< 0.5%). Hence, our analysis 
has the potential for a type II error. Analysis accord-
ing to the type of implanted DES was not possible 
due to the fact that this information was available 
only in 2 of the included studies. Finally, with the 
exception of 1 trial, our study included only RCTs 
of patients who were treated with the P2Y12 inhibi-
tor clopidogrel. The trial in which patients were 
treated with ticagrelor, prasugrel or clopidogrel did 
not report outcome based on the P2Y12 treatment 
received. Thus, it is uncertain whether the use of 
newer more potent P2Y12 inhibitors, including 
ticagrelor and prasugrel, would alter the safety and 
efficacy of prolonged DAPT.
Conclusions
This meta-analysis did not find any difference 
in efficacy outcomes between short-term and long-
-term DAPT following DES. Short-term DAPT was 
equally effective as long-term DAPT in preventing 
the primary outcome even in high-risk patients. 
However, longer duration of DAPT was found to 
be associated with increased risk of major bleeding 
in our study, in addition to increased non-cardiovas-
cular and all-cause mortality demonstrated in the 
DAPT study. Larger, adequately powered RCTs for 
low event rates are needed to confirm these findings.
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